Modulation of sphingosine-1-phosphate in ulcerative colitis

References

• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med [Internet]. 2005;353:2462–2467. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21133961
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–265.e3.
   Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med [Internet]. 2013;369(8):699–710. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1215734
   PubMed Web of Science ®Google Scholar
• Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017 Feb;66(2):199–209.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Peyrin-Biroulet L, Sturm A, et al. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - multicenter European cohort study. Dig Liver Dis. 2016 Jun;48(6):592–600.
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Van Assche G, Sturm A, et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. Dig Liver Dis. 2016 Jun;48(6):601–607.
   PubMedGoogle Scholar
• Argollo M, Fiorino G, Hindryckx P, et al. Novel therapeutic targets for inflammatory bowel disease. J Autoimmun Internet. 2017;85:103–116.
   PubMed Web of Science ®Google Scholar
• Sugahara K, Maeda Y, Shimano K, et al. Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2017 Jan;174(1):15–27.
   PubMed Web of Science ®Google Scholar
• Park SJ, Im DS. Sphingosine 1-phosphate receptor modulators and drug discovery. Biomol Ther. 2017;25(1):80–90.
   PubMed Web of Science ®Google Scholar
• Le Stunff H, Milstien S, Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem. 2004 Aug;92(5):882–899.
   PubMed Web of Science ®Google Scholar
• Pettus BJ, Bielawski J, Porcelli AM, et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J Off Publ Fed Am Soc Exp Biol. 2003 Aug;17(11):1411–1421.
   PubMed Web of Science ®Google Scholar
• Snider AJ, Kawamori T, Bradshaw SG, et al. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J Off Publ Fed Am Soc Exp Biol. 2009 Jan;23(1):143–152.
   PubMed Web of Science ®Google Scholar
• Huang W-C, Liang J, Nagahashi M, et al. Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans. FASEB J Off Publ Fed Am Soc Exp Biol. 2016 Aug;30(8):2945–2958.
   PubMed Web of Science ®Google Scholar
• Wollny T, Watek M, Durnas B, et al. Sphingosine-1-phosphate metabolism and its role in the development of inflammatory bowel disease. Int J Mol Sci. 2017 Mar;18(4):741.
   PubMed Web of Science ®Google Scholar
• Harris CM, Mittelstadt S, Banfor P, et al. Sphingosine-1-phosphate (S1P) lyase inhibition causes increased cardiac S1P levels and bradycardia in rats. J Pharmacol Exp Ther. 2016 Oct;359(1):151–158.
   PubMed Web of Science ®Google Scholar
• Pérez-Jeldres T, Tyler CJ, Boyer JD, et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists. Front Pharmacol. 2019;10(March):1–15.
   PubMedGoogle Scholar
• Blaho VA, Hla T. An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res. 2014 Aug;55(8):1596–1608.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Christopher R, Behan D, et al. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev [Internet]. 2017. DOI:10.1016/j.autrev.2017.03.007
   Web of Science ®Google Scholar
• Greenspon J, Li R, Xiao L, et al. Sphingosine-1-phosphate regulates the expression of adherens junction protein E-cadherin and enhances intestinal epithelial cell barrier function. Dig Dis Sci. 2011 May;56(5):1342–1353.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 2004 Jul;4(7):1019–1025.
   PubMed Web of Science ®Google Scholar
• Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016 Jun;173(11):1778–1792.
   PubMed Web of Science ®Google Scholar
• Ohotski J, Edwards J, Elsberger B, et al. Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. Int J Cancer. 2013 Feb;132(3):605–616.
   PubMed Web of Science ®Google Scholar
• Blankenbach KV, Schwalm S, Pfeilschifter J, et al. Sphingosine-1-phosphate receptor-2 antagonists: therapeutic potential and potential risks. Front Pharmacol. 2016;7:167.
   PubMed Web of Science ®Google Scholar
• Fryer RM, Muthukumarana A, Harrison PC, et al. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P(1)) and hypertension (S1P(3)) in rat. PLoS One. 2012;7(12):e52985.
   PubMed Web of Science ®Google Scholar
• Yu OM, Brown JH. G protein-coupled receptorand RhoA-stimulated transcriptional responses: links to inflammation, differentiation, and cell proliferation. Mol Pharmacol. 2015 Jul;88(1):171–180.
   PubMed Web of Science ®Google Scholar
• Wang W, Graeler MH, Goetzl EJ. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J Off Publ Fed Am Soc Exp Biol. 2005 Oct;19(12):1731–1733.
   PubMedGoogle Scholar
• Schulze T, Golfier S, Tabeling C, et al. Sphingosine-1-phosphate receptor 4 (S1P(4)) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model. FASEB J Off Publ Fed Am Soc Exp Biol. 2011 Nov;25(11):4024–4036.
   PubMed Web of Science ®Google Scholar
• Walzer T, Chiossone L, Chaix J, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol. 2007 Dec;8(12):1337–1344.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue E-W, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545–556.
   PubMed Web of Science ®Google Scholar
• Fragoso YD. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events. Acta Neurol Belg. 2017 Dec;117(4):821–827.
   PubMed Web of Science ®Google Scholar
• Forrest M, Sun S-Y, Hajdu R, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004 May;309(2):758–768.
   PubMed Web of Science ®Google Scholar
• Mazurais D, Robert P, Gout B, et al. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem. 2002 May;50(5):661–670.
   PubMed Web of Science ®Google Scholar
• Jeffery DR, Markowitz CE, Reder AT, et al. Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother. 2011 Feb;11(2):165–183.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med [Internet]. 2016;374(18):1754–1762. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1513248?query=TOC
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, D’Haens G, et al. Safety and efficacy of long-term treatment with ozanimod, and oral S1P receptor modulator, in moderate to severe ulcerative colitis: TOUCHSTONE extension. UEG J 2016;2(Suppl 1).
   Google Scholar
• Clinicaltrials.gov. NCT02435992: safety and efficacy trial of RPC1063 for moderate to severe ulcerative colitis. [cited 2019 Jul 08]. https://clinicaltrials.gov/ct2/show/NCT02435992
   Google Scholar
• Clinicaltrials.gov. NCT02531126: open-label extension of RPC1063 as therapy for moderate to severe ulcerative colitis. [cited 2019 Jul 08]. https://clinicaltrials.gov/ct2/show/NCT02531126
   Google Scholar
• Sandborn WJ, Peyrin‐Biroulet L, Trokan L, et al. A randomized, double‐blind, placebo‐controlled trial of a selective, oral sphingosine 1‐ phosphate (S1P) receptor modulator, etrasimod (APD334), in moderate to severe ulcerative colitis (UC): results from the OASIS study. ACG [Internet]. 2018. Available from: https://www.eventscribe.com/2018/ACG/fsPopup.asp?Mode=presInfo&PresentationID=442125
   Google Scholar
• Peyrin-Biroulet L, Panés J, Chiorean M, et al. OP09 Histological remission and mucosal healing in a randomised, placebo-controlled, Phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis. J Crohns colitis. 2019;13:S006-S006.
   Web of Science ®Google Scholar
• Vermeire S, Panés J, Chiorean M et al. Long-term efficacy and safety of etrasimod for ulcerative colitis: results from the open- label extension of the OASIS study. Abstr UEGW. 2009
   Google Scholar
• Yarur A, Jairath V, Zhang J et al. Correlation of fecal calprotectin and C‐reactive protein concentrations with clinical outcomes and endoscopic disease activity in patients with ulcerative colitis receiving induction therapy with etrasimod. Abstr DDW 2019.
   Google Scholar